Skip to main content
padlock icon - secure page this page is secure

Knockdown of FBXO39 inhibits proliferation and promotes apoptosis of human osteosarcoma U2OS cells

Buy Article:

$42.00 + tax (Refund Policy)

Fbox proteins are essential components of the SkpcullinFbox complex (a type of E3 ubiquitin ligase), and participate in cell cycle and immune responses through the ubiquitin proteasome system. Fbox protein 39 (FBXO39) belongs to the Fbox family, which has been reported to be associated with cancer oncogenesis and progression. The present study aimed to investigate the role of FBXO39 in osteosarcoma (OS) cell proliferation and apoptosis in vitro. It was demonstrated that U2OS cells exhibited high expression of FBXO39 compared with HOS and SaOS2 osteosarcoma cells. Thus, knockdown of FBXO39 was performed using lentivirusmediated short hairpin RNA (shRNA) transfection to validate the effect of FBXO39 in U2OS cells. Western blotting and RTqPCR analysis were used to confirm the efficiency of infection by analyzing the expression level of FBXO39. Using Celigobased cell counting and MTT assays, it was demonstrated that FBXO39 knockdown significantly reduced the rate of cell proliferation compared with control. Caspase 3/7 activity assays and fluorescenceactivated cell sorting confirmed the induction of apoptosis in U2OS cells following FBXO39 knockdown. In conclusion, it was demonstrated that FBXO39 knockdown may significantly inhibit proliferation and promote apoptosis of U2OS cells. Thus, FBXO39 may serve an important role in OS progression.
No Reference information available - sign in for access.
No Citation information available - sign in for access.
No Supplementary Data.
No Article Media
No Metrics

Document Type: Research Article

Affiliations: 1: Department of Joint and Musculoskeletal Tumor, The First Affiliated Hospital of Shenzhen University, Shenzhen Second People's Hospital, Shenzhen, Guangdong 518000, P.R. China 2: Musculoskeletal Tumor Center, Peking University People's Hospital, Beijing 100044, P.R. China

Publication date: January 1, 2018

More about this publication?
  • Oncology Letters is a monthly, peer-reviewed journal, available in print and online, that focuses on all aspects of clinical oncology, as well as in vitro and in vivo experimental model systems relevant to the mechanisms of disease.

    The principal aim of Oncology Letters is to provide the prompt publication of original studies of high quality that pertain to clinical oncology, chemotherapy, oncogenes, carcinogenesis, metastasis, epidemiology and viral oncology in the form of original research, reviews and case reports.
  • Editorial Board
  • Information for Authors
  • Submit a Paper
  • Subscribe to this Title
  • Information for Advertisers
  • Terms & Conditions
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more